Browsing by Subject "Tumours"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    New insights into the cytoplasmic function of PML
    (Murcia : F. Hernández, 2007) Salomoni, P.; Bellodi, C.
    PML is a tumour suppressor inactivated in Acute Promyelocytic Leukaemia (APL). PML is the essential component of a subnuclear structure called the PML nuclear body (PML-NB), which is disrupted in APL. By targeting different cellular proteins to this structure, PML can either hamper or potentiate their functions. The PML transcript undergoes alternative splicing to generate both nuclear and cytoplasmic isoforms. Most of the research in this field has focused its attention on studying nuclear PML. Nevertheless, new exciting studies show that cytoplasmic PML may control essential cellular functions, thus opening new avenues for investigation.
  • Thumbnail Image
    Publication
    Open Access
    NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases
    (Murcia: F. Hernández, 2007) Sun, X-F.; Zhang, H.
    Nuclear factor-kB (NF-kB) is responsible for the expression by regulating many genes for immune response, cell adhesion, differentiation, proliferation, angiogenesis and apoptosis. The function of NF-kB is inhibited by binding to NF-kB inhibitor (IkB), and imbalance of NF-kB and IkB has been associated with development of many diseases, including tumours. In this review, we focus on polymorphisms of the NFKB and NFKBI genes in relation to development of common inflammatory diseases including ulcerative colitis (UC), Crohn’s disease (CD), rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, giant cell arthritis, type 1 diabetes, multiple sclerosis, celiac disease, and Parkinson’s disease, as well as susceptibility of several cancers, such as oral squamous cell carcinoma, colorectal cancer (CRC), hepatocellular carcinoma, breast cancer and myeloma.